{
    "nct_id": "NCT03678493",
    "official_title": "A Randomized Placebo-Controlled Clinical Trial of Fecal Microbiota Transplantation in Patients With Acute Myeloid Leukemia and Allogeneic Hematopoietic Cell Transplantation Recipients",
    "inclusion_criteria": "* Ageâ‰¥ 18 years\n* Cohort A: Patients undergoing intensive induction chemotherapy for acute myeloid leukemia (AML; newly diagnosed or relapsed/refractory).\n\n  * Any intensive regimen with planned ~4 weeks of inpatient stay\n* Cohort B: Allo-HCT patients\n\n  * Any allogeneic transplant regimen with planned GVHD prophylaxis containing generic IV Mycophenolate Mofetil (MMF) and tacrolimus (Tac)\n* Sexually active females of childbearing potential and males with partners of child-bearing potential must agree to use adequate birth control until at least six months post-FMT/placebo\n* Voluntary written consent signed before performance of any study-related procedure not part of normal medical care\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Planned continuation of antibacterial antibiotics after the first neutrophil recovery (ANC > 1,000)\n* Patients who are currently receiving or recently received (within 28 days) other investigational agents.\n* Pregnant or breast feeding. The FDA has not classified this agent into a specified pregnancy category. Females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy",
    "miscellaneous_criteria": ""
}